Editorial Material
Multidisciplinary Sciences
Dewey Murdick
Summary: Knowing what policymakers should know is important, but it is equally important to help them effectively utilize this information.
Review
Medicine, General & Internal
Yan Jiang, Zhen-Lun Huang
Summary: This review discusses the recent advances in targeting calcitonin gene-related peptides for the treatment of menstrual migraines. Both anti-CGRP mAbs and CGRP receptor antagonists have shown good efficacy and safety in controlling menstrual migraines.
Article
Clinical Neurology
Andreas Straube, Gregor Broessner, Charly Gaul, Xenia Hamann, Joachim Hipp, Torsten Kraya, Lars Neeb
Summary: This study evaluated the effectiveness of switching to fremanezumab in patients who had previously failed treatment with other anti-CGRP pathway monoclonal antibodies. The results showed that approximately 42.8% of patients experienced a reduction of 50% or more in their monthly migraine days after switching to fremanezumab. Therefore, switching to fremanezumab may be a promising option for patients who have had poor response or inadequate efficacy with prior anti-CGRP pathway mAb use.
JOURNAL OF HEADACHE AND PAIN
(2023)
Review
Biochemistry & Molecular Biology
Adriano Bonura, Nicoletta Brunelli, Marilena Marcosano, Gianmarco Iaccarino, Luisa Fofi, Fabrizio Vernieri, Claudia Altamura
Summary: The calcitonin gene-related peptide (CGRP) is a neuropeptide with complex systemic impact beyond nociception. It plays a crucial role in vasodilation, inflammation, intestinal motility, and apoptosis. CGRP has contradictory effects, acting as a potent vasodilator in the cardiovascular system but not inducing arterial hypertension. It also exhibits both anti-inflammatory and pro-inflammatory effects as an immunomodulator.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, Yasuo Haruyama, Hiroaki Fujita, Kei Funakoshi, Koichi Hirata
Summary: This study retrospectively assessed the effect of galcanezumab in the first week after administration and found that it had a significant effect. The number of weekly migraine days and monthly migraine days significantly improved after 1-3 months of treatment. Additionally, the response rate at week 1 could predict the response rate at 3 months.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, Carmelina Maria Costa, Bruno Colombo, Paola Torelli, Simone Quintana, Sabina Cevoli, Valentina Favoni, Florindo D'Onofrio, Gabriella Egeo, Renata Rao, Massimo Filippi, Piero Barbanti, Claudia Altamura
Summary: The study aimed to evaluate the effect of discontinuing mAbs anti-CGRP on migraine patients. Results showed that migraine frequency and disability gradually increased after stopping the treatment, but most patients did not relapse to medication overuse or chronic migraine.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Clinical Neurology
Umberto Pensato, Carlo Baraldi, Valentina Favoni, Davide Mascarella, Eleonora Matteo, Giorgia Andrini, Maria Michela Cainazzo, Pietro Cortelli, Giulia Pierangeli, Simona Guerzoni, Sabina Cevoli
Summary: This study suggests that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients regardless of detoxification, but further research is needed to draw definitive conclusions.
Article
Medicine, General & Internal
Ilana D. Breen, Caitlin M. Brumfiel, Meera H. Patel, Richard J. Butterfield, Juliana H. VanderPluym, Leroy Griffing, Mark R. Pittelkow, Aaron R. Mangold
Summary: The study found that microvascular complications of CGRP antagonist use in patients with underlying RP are uncommon, but caution is still needed when considering the use of these agents in these patients.
Article
Dermatology
Twan Sia, Taylor Webb, Shufeng Li, Leon S. Moskatel, Anne Lynn S. Chang
Summary: This exploratory retrospective study examined the effect of CGRP monoclonal antibodies (mAbs) on rosacea in patients with migraines. The majority of patients experienced improvement in rosacea severity after receiving CGRP mAbs. Prospective, placebo-controlled clinical trials are needed to further evaluate the use of CGRP mAbs in rosacea.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Editorial Material
Clinical Neurology
Enrico Bentivegna, Dilara Onan, Paolo Martelletti
Summary: Migraine is the main cause of work disability in young women and the second in the general population. Preventive treatment can improve the quality of life by reducing the frequency and intensity of attacks. However, there are significant gaps in the global health systems in terms of optimal management of preventive therapy. Traditional medications with known adverse effects are still considered the standard of care for migraine prevention in many cases, while the use of calcitonin gene-related peptide (CGRP) receptor antagonists is limited due to their high cost. There are also shortcomings in migraine management by general practitioners and a lack of patient education, resulting in delays in referring patients to specialized headache centers. We expect the headache medicine community to address these gaps in preventive treatment of migraine in the coming years.
NEUROLOGY AND THERAPY
(2023)
Article
Clinical Neurology
Chun-Pai Yang, Bing-Yan Zeng, Ching-Mao Chang, Po-Hsuan Shih, Cheng-Chia Yang, Ping-Tao Tseng, Shuu-Jiun Wang
Summary: This study aimed to compare the efficacy and acceptability of CGRP mAbs with onabotulinumtoxinA or topiramate for chronic migraine. Results showed that a single 300 mg dose of eptinezumab was most effective in improving monthly migraine days, while a regimen of 675 mg fremanezumab in the first month followed by 225 mg showed the highest response rate.
Article
Clinical Neurology
Giorgio Lambru, Valeria Caponnetto, Bethany Hill, Susanna Ratti, Simona Sacco, Madeleine Murphy, Jessica Briscoe, Anna P. Andreou
Summary: Switching to calcitonin gene-related peptide monoclonal antibodies against the ligand may benefit migraine patients who have a poor response to a calcitonin gene-related peptide monoclonal antibody against the receptor. In a long-term analysis, 35.9% of patients who switched from erenumab to fremanezumab achieved a meaningful reduction in monthly migraine days. The number of responders increased from 10 to 14 after six months of treatment with fremanezumab.
Article
Immunology
Susan Pederson, David M. Biondi, Brent Allan, Roger Cady, Barbara Schaeffler, Brian Baker, John Latham
Summary: Across five clinical trials, the immunogenicity of eptinezumab was characterized by low titer and transient ADA and NAb responses, with no clinically meaningful impact on efficacy and safety profiles. The onset of detectable ADA occurred at week 8, peaked at week 24, and declined steadily thereafter, regardless of eptinezumab dose level or number of doses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi, Chiara Zecca
Summary: This study aimed to evaluate the safety of migraine preventive monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy. The results showed no signals of foeto-maternal toxicity according to safety reports.
Article
Chemistry, Medicinal
Stephen E. Mercer, Prasad V. Chaturvedula, Charles M. Conway, Deborah A. Cook, Carl D. Davis, Sokhom S. Pin, Robert Macci, Richard Schartman, Laura J. Signor, Kimberly A. Widmann, Valerie J. Whiterock, Ping Chen, Cen Xu, John J. Herbst, Walter A. Kostich, George Thalody, John E. Macor, Gene M. Dubowchik
Summary: CGRP receptor antagonist zavegepant has demonstrated efficacy in acute migraine treatment but with low oral bioavailability. By designing a series of compounds, researchers have successfully improved oral bioavailability of a compound while maintaining high affinity binding and in vivo efficacy.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2021)
Article
Clinical Neurology
Linda Al-Hassany, Tessa de Vries, Johannes A. Carpay, Antoinette MaassenVanDenBrink
Summary: Inhibition of the calcitonin gene-related peptide pathway may lead to erectile dysfunction in male migraine patients, highlighting the importance of further research into this potential side effect.
Article
Clinical Neurology
Francesca Puledda, Maria Dolores Villar-Martinez, Peter J. Goadsby
Summary: This article describes a case of intermittent visual snow syndrome that transforms into a persistent form following a posterior circulation stroke. It suggests that visual snow syndrome may be caused by an underlying brain disorder and highlights the importance of the cerebellum in the pathophysiology of this condition.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Mateusz Chwolka, Peter J. Goadsby, Andreas R. Gantenbein
Summary: This study presents five patients for whom it was difficult to distinguish between migraine and cluster headache. These patients had phenotypic features that could be attributed to both disorders. A correct diagnosis is crucial for selecting the appropriate treatment approach, especially if initial treatment is not successful and further diagnostic and therapeutic options should be considered.
Review
Clinical Neurology
Miguel Ruiz, Alexandra Cocores, Antonella Tosti, Peter J. Goadsby, Teshamae S. Monteith
Summary: This study describes two cases of temporary hair loss associated with erenumab and reviews the FDA Adverse Event Reporting System. The study found that there were the most reports of hair loss with erenumab, followed by galcanezumab and fremanezumab. Most of the events occurred in women and were non-serious. The potential mechanism of drug-induced hair loss targeting calcitonin gene-related peptide or its receptor may involve disruptions in microvascular circulation and other homeostatic mechanisms.
Review
Clinical Neurology
Edoardo Caronna, Thomas C. van den Hoek, Hayrunnisa Bolay, David Garcia-Azorin, Ana Beatriz Gago-Veiga, Massimiliano Valeriani, Tsubasa Takizawa, Karl Messlinger, Robert E. Shapiro, Peter J. Goadsby, Messoud Ashina, Cristina Tassorelli, Hans-Christoph Diener, Gisela M. Terwindt, Patricia Pozo-Rosich
Summary: This article summarizes the knowledge on the epidemiology, pathophysiology, and management of secondary headache associated with SARS-CoV-2 infection and vaccination, as well as their impact on primary headache disorders. It was found that headache is a common symptom of both acute and post-acute phase of SARS-CoV-2 infection, and specific effective therapeutic options are currently lacking. Headache attributed to SARS-CoV-2 vaccinations is also common, but its pathophysiology remains unclear. People with primary headache disorders are more likely to experience headache during the acute phase of COVID-19 and after vaccination.
Article
Clinical Neurology
Richard B. Lipton, Andrew Blumenfeld, Christopher M. Jensen, Robert Croop, Alexandra Thiry, Gilbert L'Italien, Beth A. Morris, Vladimir Coric, Peter J. Goadsby
Summary: This post-hoc analysis examined the efficacy of riemegpant in treating migraine in adults based on triptan treatment experience. The results showed that riemegpant was effective in all groups, except for triptan-naive participants.
Article
Clinical Neurology
Peter J. Goadsby, Piero Barbanti, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjorn Sperling
Summary: In a clinical trial, eptinezumab showed significant improvements in patient health and quality of life compared to placebo.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Francesca Puledda, Samaira Younis, Eva-Maria Huessler, Faraidoon Haghdoost, Marco Lisicki, Peter J. Goadsby, Cristina Tassorelli
Summary: We conducted a network meta-analysis to evaluate the efficacy and safety of newly developed drugs for the acute treatment of migraine attacks. The results showed that lasmiditan 200 mg had the highest pain relief, but it was also associated with high levels of dizziness, nausea, and somnolence. Rimegepant had slightly lower, but comparable efficacy to lasmiditan, while ubrogepant had the best tolerability profile.
Article
Clinical Neurology
Nazia Karsan, Ray Pyari Bose, Owen O'Daly, Fernando Zelaya, Peter J. Goadsby
Summary: This study identified significant regional changes in cerebral blood flow associated with premonitory symptoms induced by NTG. These findings are crucial for understanding the mechanisms underlying migraine attacks and alterations in neuronal function.
Article
Clinical Neurology
Francesca Puledda, Elisa Martins Silva, Kanokrat Suwanlaong, Peter J. Goadsby
Summary: Migraine is a common neurological disorder with complex neurobiology, affecting both central and peripheral nervous systems. Recent advancements in understanding its pathophysiology have led to the development of novel treatments, which are changing the clinical approach to the disease globally.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Alexander Gordon, Thomas Roe, Maria Dolores Villar-Martinez, David Moreno-Ajona, Peter J. Goadsby, Jan Hoffmann
Summary: In this systematic review, GON blockade was found to be effective and safe for preventing cluster headaches. The treatment resulted in a significant reduction in the frequency, severity, and duration of attacks, as well as an increased proportion of patients responding to treatment. However, there were instances of potentially irreversible adverse effects. Therefore, GON blockade is considered a safe and effective preventive therapy when administered with appropriate injection volume and concurrent prophylaxis.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Health Care Sciences & Services
Linus Jonsson, Stephane A. Regnier, Steven Kymes, Susanne F. Awad, Brian Talon, Xin Ying Lee, Peter J. Goadsby
Summary: This post hoc analysis aimed to estimate the therapeutic effect of eptinezumab on health utilities and determine the extent to which changes in monthly migraine days explain the changes in health utilities. The study found that reducing monthly migraine days was associated with an increase in health utility scores. Patients treated with eptinezumab had higher utility scores compared to those treated with placebo, indicating a treatment-specific impact on health utility scores in addition to the reduction in migraine days.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2023)
Article
Clinical Neurology
Arne May, Stefan J. Evers, Peter Goadsby, Massimo Leone, Gian Camillo Manzoni, Julio Pascual, Vanessa Carvalho, Michele Romoli, Katina Aleksovska, Patricia H. Pozo-Rosich, Rigmor Jensen, European Academy Neurology Task Force
Summary: Cluster headache is a rare and disabling primary headache disorder that greatly affects patients' quality of life. This study provides evidence-based recommendations for the treatment of cluster headache. Oxygen therapy with high flow, subcutaneous sumatriptan, verapamil, corticosteroids, lithium, topiramate, galcanezumab, noninvasive vagus nerve stimulation, and greater occipital nerve block are recommended treatments. Electrical stimulation of the greater occipital nerve is not recommended due to side effects.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Behavioral Sciences
Katarina Ilic, Rita Bertani, Neda Lapteva, Panagis Drakatos, Alessio Delogu, Kausar Raheel, Matthew Soteriou, Carlotta Mutti, Joerg Steier, David W. Carmichael, Peter J. Goadsby, Adam Ockelford, Ivana Rosenzweig
Summary: This article systematically reviews the presence and nature of visual imagery in the dreams of congenitally blind people. Studies suggest that the blind occipital cortex may integrate non-visual sensory inputs and generate visuo-spatial impressions. Visual impressions have also been reported in near-death or out-of-body experiences of blind individuals. Understanding the mechanistic nature of these visual impressions could have potential implications for utilizing neuroplasticity in the treatment of neurodisability.
FRONTIERS IN INTEGRATIVE NEUROSCIENCE
(2023)
Meeting Abstract
Clinical Neurology
Linda Al-Hassany, Katie M. Linstra, Gisela M. Terwindt, Marieke J. Wermer, Antoinette MaassenVanDenBrink
